Skip to content

US · KURA · BIOTECHNOLOGY

Kura Oncology, Inc. (KURA) intrinsic value and stock valuation

$6.91as of 2026-11-21 · Mkt cap 816.72M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Kura Oncology, Inc. DCF and intrinsic value

InvestorsCraft values KURA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from KURA’s statements →

Kura Oncology, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Diego, CA 92121 kuraoncology.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$67.5M
20112025
Net income
-$-278.67M
20112025
Free cash flow
-$-70.7M
20112025
Total equity
$174.1M-22.2% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$67.5M$53.9M$0.00$0.00$0.00
Operating income-$-303.63M-$-193.19M-$-165.8M-$-139.87M-$-131.26M
Net income-$-278.67M-$-173.98M-$-152.63M-$-135.84M-$-130.47M
EPSd-$-3.18M-$-2.02M-$-2.08M-$-2.03M-$-1.97M
Operating cash flow-$-64.06M$134.3M-$-124.82M-$-110.06M-$-104.55M
Capital expenditure-$-6.64M-$-470K-$-170K-$-630K-$-1.15M
Free cash flow-$-70.7M$133.8M-$-124.99M-$-110.69M-$-105.7M
Total assets$738.4M$760.2M$448.9M$456.3M$534.1M
Total debt$20.5M$16.6M$17.2M$14M$6.88M
Net debt-$-128.64M-$-207.87M-$-20.12M-$-37.78M-$-83.8M
Total equity$174.1M$413.6M$397.3M$420.3M$506.6M
Cash and short-term investments$667.2M$727.4M$424M$438M$518M
Income statement
20252024202320222021
Revenue$67.5M$53.9M$0.00$0.00$0.00
Cost of revenue$60K$0.00$850K$0.00$0.00
Gross profit$67.4M$53.9M-$-850K$0.00$0.00
Research and development expenses$251.1M$170M$115.2M$92.8M$84.7M
Selling, general and administrative expenses$120M$77.1M$50.6M$47.1M$46.5M
Other expenses$0.00$0.00-$-850K$0.00$0.00
Operating expenses$371.1M$247.1M$165M$139.9M$131.3M
Cost and expenses$371.1M$247.1M$165.8M$139.9M$131.3M
Interest income$26.8M$22.9M$14.7M$4.25M$1.21M
Interest expense$1.51M$1.62M$1.55M$230K$410K
Depreciation and amortization$1.03M$850K$850K$760K$560K
Ebitda-$-275.82M-$-169.5M-$-150.23M-$-134.85M-$-129.49M
Operating income-$-303.63M-$-193.19M-$-165.8M-$-139.87M-$-131.26M
Total other income/expenses, net$25.3M$21.2M$13.2M$4.03M$790K
Income before tax-$-278.37M-$-171.97M-$-152.63M-$-135.84M-$-130.47M
Income tax expense$300K$2.02M$0.00$0.00$0.00
Net income-$-278.67M-$-173.98M-$-152.63M-$-135.84M-$-130.47M
Weighted average shares outstanding$87.7M$86.2M$73.2M$67M$66.4M
Weighted average diluted shares outstanding$87.7M$86.2M$73.2M$67M$66.4M
Balance sheet
20252024202320222021
Cash and short-term investments$667.2M$727.4M$424M$438M$518M
Net receivables$12.6M$0.00$0.00$0.00$0.00
Inventory$410K$0.00$0.00$0.00$0.00
Total current assets$708.7M$744.8M$432.5M$446.4M$522.3M
Property, plant and equipment, net$15.2M$7.49M$8.85M$6.38M$8.25M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$29.7M$15.3M$16.5M$9.88M$11.8M
Total assets$738.4M$760.2M$448.9M$456.3M$534.1M
Accounts payable$5.02M$1.47M$2.3M$1.53M$3.24M
Short-term debt$1.28M$4.49M$1.51M$2.32M$2.26M
Deferred revenue$49M$24.3M$0.00$0.00$0.00
Total current liabilities$117M$78.7M$35.3M$24.1M$22.5M
Long-term debt$19.2M$12.1M$15.7M$11.7M$4.61M
Deferred revenue, non-current$424.9M$253.9M$0.00$0.00$0.00
Total non-current liabilities$447.3M$267.8M$16.4M$12M$4.99M
Capital lease obligations$10.8M$7.07M$7.87M$4.87M$6.88M
Total liabilities$564.2M$346.5M$51.7M$36M$27.4M
Common stock$10K$10K$10K$10K$10K
Retained earnings-$-1.17B-$-895.42M-$-721.44M-$-568.81M-$-432.97M
Accumulated other comprehensive income (loss)$1.02M$760K-$-1.27M-$-8.03M-$-1.79M
Total equity$174.1M$413.6M$397.3M$420.3M$506.6M
Total investments$518.1M$502.9M$386.6M$386.2M$427.3M
Total debt$20.5M$16.6M$17.2M$14M$6.88M
Net debt-$-128.64M-$-207.87M-$-20.12M-$-37.78M-$-83.8M
Cash flow statement
20252024202320222021
Net income-$-278.67M-$-173.98M-$-152.63M-$-135.84M-$-130.47M
Depreciation and amortization-$-7.46M$850K$850K$760K$560K
Stock-based compensation$37.1M$33.9M$28.1M$26.3M$23.6M
Change in working capital$184.4M$286.2M$7.82M-$-2.98M-$-3.22M
Accounts receivable-$-6.74M$0.00$0.00$0.00$0.00
Inventory-$-410K$0.00$0.00$0.00$0.00
Accounts payable$4.5M$15.2M$10.3M-$-800K-$-2.52M
Net cash provided by operating activities-$-64.06M$134.3M-$-124.82M-$-110.06M-$-104.55M
Investments in property, plant and equipment-$-6.64M-$-470K-$-170K-$-630K-$-1.15M
Acquisitions, net$0.00$0.00$0.00-$-30K$130K
Net cash used for investing activities-$-13.1M-$-101.59M$15.6M$32.6M-$-126.83M
Common stock issued$1.79M$145.8M$93.6M$24.7M$4.43M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.79M$154.4M$94.8M$38.6M-$-3.44M
Net change in cash-$-75.36M$187.1M-$-14.48M-$-38.87M-$-234.82M
Cash at end of period$149.1M$224.5M$37.3M$52M$90.9M
Operating cash flow-$-64.06M$134.3M-$-124.82M-$-110.06M-$-104.55M
Capital expenditure-$-6.64M-$-470K-$-170K-$-630K-$-1.15M
Free cash flow-$-70.7M$133.8M-$-124.99M-$-110.69M-$-105.7M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Kura Oncology, Inc.

        Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

        CEO
        Troy Wilson
        Employees
        260
        Beta
        0.35

        Explore

        Frequently asked questions

        What is the intrinsic value of Kura Oncology, Inc. (KURA)?

        Kura Oncology, Inc. (KURA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is KURA undervalued?

        KURA trades at a price of $6.91 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.